Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974833 | 1.00 | CYP2A6 (0.37) | CYP2A6CHRNB2CHRNA4CHRM4NNMT | |
| SCHEMBL314949 | 0.92 | CYP11B1 (0.37) | CYP2A6MKNK1MKNK2HSD17B1HSD17B2 | |
| SCHEMBL314948 | 0.92 | CYP11B1 (0.37) | CYP2A6MKNK1MKNK2HSD17B1HSD17B2 | |
| SCHEMBL3999819 | 0.85 | CHRNB2 (0.35) | CHRNB2CHRNA4 | |
| SCHEMBL3999824 | 0.85 | CHRNB2 (0.35) | CHRNB2CHRNA4 | |
| SCHEMBL1973290 | 0.83 | CHRM4 (0.35) | CHRNB2CHRNA4CHRM4 | |
| SCHEMBL1973288 | 0.83 | CHRM4 (0.35) | CHRNB2CHRNA4CHRM4 | |
| SCHEMBL2411109 | 0.83 | HSD17B1 (0.49) | CYP2A6MKNK1MKNK2HSD17B1HSD17B2 | |
| SCHEMBL2411104 | 0.83 | HSD17B1 (0.49) | CYP2A6MKNK1MKNK2HSD17B1HSD17B2 | |
| SCHEMBL314993 | 0.83 | HSD17B1 (0.38) | CYP2A6MKNK1MKNK2HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1668021-B1 | NOVEL THIOXYLOSE COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF IN THERAPEUTICS | FOURNIER LAB SA (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-7470671-B2 | Thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therapeutics | LABORATOIRE FOURNIER (FR) | 2008-12-30 | — | — | US | disclosed |
| US-20070054955-A1 | Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics. | LABORATOIRES FOURNIER S.A. (FR) | 2007-03-08 | — | — | US | disclosed |
| EP-1668021-A2 | NOVEL THIOXYLOSE COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF IN THERAPEUTICS | LABORATOIRES FOURNIER S.A. (FR) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030785-A2 | NOVEL THIOXYLOSE COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF IN THERAPEUTICS | LABORATOIRES FOURNIER S.A. (FR) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054955-A1 | Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics. | NOTUM, STS, AGPS | CYP2A6 80/4885CHRNB2 4512/4885CHRNA4 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.